Vascular risk in obesity: Facts, misconceptions and the unknown

Diabetes and Vascular Disease Research

Volumn 14, Issue 1, 2017, Pages 2-13

  King, Rhodri J ^a   Ajjan, Ramzi A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

cardiovascular disease; hypofibrinolysis; inflammation; Obesity; thrombosis

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN; ADIPOCYTOKINE; ANTIOBESITY AGENT; AUTACOID;

ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BARIATRIC SURGERY; BEHAVIOR MODIFICATION; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM CELL; EXERCISE; GLYCEMIC INDEX; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LOW CALORY DIET; LOW CARBOHYDRATE DIET; LOW FAT DIET; MEDITERRANEAN DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; ROUX-EN-Y GASTRIC BYPASS; THERAPY EFFECT; THROMBOSIS; VASCULAR DISEASE; WEIGHT REDUCTION; BLOOD CLOTTING; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; PROTECTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

ADIPOKINES; ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BLOOD COAGULATION; HUMANS; INFLAMMATION MEDIATORS; OBESITY; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SIGNAL TRANSDUCTION; VASCULAR DISEASES; WEIGHT LOSS;

EID: 85003972562     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164116675488     Document Type: Review

References (107)

1. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. The biology of haemostasis and thrombosis. N Engl J Med 2006; 355: 763-778.
2. Aronne LJ, Brown WV, Isoldi KK,. Cardiovascular disease in obesity: a review of related risk factors and risk-reduction strategies. J Clin Lipidol 2007; 1: 575-582.
3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
4. Goldberg RB,. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94: 3171-3182.
5. Herder C, Haastert B, Muller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005; 54: S11-S17.
6. Karpe F, Pinnick KE,. Biology of upper-body and lower-body adipose tissue-link to whole-body phenotypes. Nat Rev Endocrinol 2015; 11: 90-100.
7. Gaborit B, Jacquier A, Kober F, et al. Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. J Am Coll Cardiol 2012; 60: 1381-1389.
8. De Vriese AS, Verbeuren TJ, Van d V, et al. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-974.
9. Naseem KM,. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005; 26: 33-65.
10. Tousoulis D, Davies G, Stefanadis C, et al. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993-997.
11. Levi M, van der Poll T,. Inflammation and coagulation. Crit Care Med 2010; 38: S26-S34.
12. Cirillo P, Golino P, Calabro P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005; 68: 47-55.
13. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
14. Mamane Y, Chung Chan C, Lavallee G, et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 2009; 58: 2006-2017.
15. Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010-1013.
16. Lumeng CN, Bodzin JL, Saltiel AR,. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
17. Gustafson B,. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17: 332-341.
18. Amano SU, Cohen JL, Vangala P, et al. Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metabolism 2014; 19: 162-171.
19. Taskinen MR,. Lipoprotein lipase in diabetes. Diabetes Metab Rev 1987; 3: 551-570.
20. Cancello R, Clement K,. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 2006; 113: 1141-1147.
21. Berg AH, Lin Y, Lisanti MP, et al. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab 2004; 287: E1178-E1188.
22. Pasceri V, Willerson JT, Yeh ET,. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
23. Van Gaal LF, Mertens IL, De Block CE,. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
24. Hoekstra T, Geleijnse JM, Schouten EG, et al. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-872.
25. Siklar Z, Ocal G, Berberoglu M, et al. Evaluation of hypercoagulability in obese children with thrombin generation test and microparticle release: effect of metabolic parameters. Clin Appl Thromb Hemost 2011; 17: 585-589.
26. Adams RL, Bird RJ,. Review article: coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants. Nephrology 2009; 14: 462-470.
27. Ajjan RA, Grant PJ,. Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. Expert Rev Cardiovasc Ther 2005; 3: 1047-1059.
28. Hess K, Grant PJ,. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; 105: S43-S54.
29. Samad F, Pandey M, Loskutoff DJ,. Regulation of tissue factor gene expression in obesity. Blood 2001; 98: 3353-3358.
30. Devaraj S, Xu DY, Jialal I,. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.
31. Langer F, Spath B, Fischer C, et al. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood 2013; 121: 2324-2335.
32. Samad F, Ruf W,. Inflammation, obesity, and thrombosis. Blood 2013; 122: 3415-3422.
33. Davi G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-2014.
34. Santilli F, Vazzana N, Liani R, et al. Platelet activation in obesity and metabolic syndrome. Obes Rev 2012; 13: 27-42.
35. Franco M, Bilal U, Ordunez P, et al. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. BMJ 2013; 346: f1515.
36. Parikh P, McDaniel MC, Ashen MD, et al. Diets and cardiovascular disease: an evidence-based assessment. J Am Coll Cardiol 2005; 45: 1379-1387.
37. Ho TP, Zhao X, Courville AB, et al. Effects of a 12-month moderate weight loss intervention on insulin sensitivity and inflammation status in nondiabetic overweight and obese subjects. Horm Metab Res 2014; 47: 289-296.
38. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440-1446.
39. Fito M, Guxens M, Corella D, et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med 2007; 167: 1195-1203.
40. Foo J, Krebs J, Hayes MT, et al. Studies in insulin resistance following very low calorie diet and/or gastric bypass surgery. Obes Surg 2011; 21: 1914-1920.
41. Aziz CB, Omar N, Abdullah WZ, et al. Reduced fibrinogen, fibrinolytic biomarkers, and physical parameters after a weight-loss program in obese subjects. N Am J Med Sci 2014; 6: 377-382.
42. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-1290.
43. de LM, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.
44. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154.
45. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014; 2: 474-480.
46. Lavie CJ, Arena R, Swift DL, et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res 2015; 117: 207-219.
47. Swift DL, Johannsen NM, Lavie CJ, et al. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis 2014; 56: 441-447.
48. Barry VW, Baruth M, Beets MW, et al. Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis 2014; 56: 382-390.
49. Bouchonville M, Armamento-Villareal R, Shah K, et al. Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial. Int J Obes 2014; 38: 423-431.
50. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.
51. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-172.
52. Yu CC, Li AM, Chan KO, et al. Orlistat improves endothelial function in obese adolescents: a randomised trial. J Paediatr Child Health 2013; 49: 969-975.
53. Samuelsson L, Gottsater A, Lindgarde F,. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003; 5: 195-201.
54. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity 2009; 17: 30-39.
55. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
56. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013; 21: 935-943.
57. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity 2011; 19: 110-120.
58. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-256.
59. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-3077.
60. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 201225; 367: 1577-1579.
61. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
62. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
63. Blonde L, Russell-Jones D,. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11: 26-34.
64. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
65. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes 2013; 37: 1443-1451.
66. Shiraki A, Oyama J, Komoda H, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012; 221: 375-382.
67. Ding L, Zhang J,. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 2012; 33: 75-81.
68. Lorber D,. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2013; 31: 238-249.
69. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166: 823-830.
70. Astrup A, Rossner S, Van GL, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
71. Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013; 33: 2252-2260.
72. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 1491-1499.
73. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 22.
74. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 90-95.
75. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322.
76. Sjostrom L,. Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219-234.
77. Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol 2011; 108: 1499-1507.
78. Batsis JA, Sarr MG, Collazo-Clavell ML, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol 2008; 102: 930-937.
79. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704.
80. Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311: 2297-2304.
81. Tschoner A, Sturm W, Engl J, et al. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr Metab Cardiovasc Dis 2012; 22: 340-346.
82. Dawson AJ, Sathyapalan T, Sedman P, et al. Insulin resistance and cardiovascular risk marker evaluation in morbid obesity 12 months after bariatric surgery compared to weight-matched controls. Obes Surg 2014; 24: 349-358.
83. Vazzana N, Guagnano MT, Aceto L, et al. Thromboxane-dependent platelet activation after gastric banding for obesity. JAMA Surg 2015; 150: 179-180.
84. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65.
85. Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev 2014; 8: CD003641.
86. O'Brien PE, MacDonald L, Anderson M, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 2013; 257: 87-94.
87. Dhoot J, Tariq S, Erande A, et al. Effect of morbid obesity on in-hospital mortality and coronary revascularization outcomes after acute myocardial infarction in the United States. Am J Cardiol 2013; 111: 1104-1110.
88. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309: 71-82.
89. Wang ZJ, Zhou YJ, Galper BZ, et al. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart 2015; 101: 1631-1638.
90. Lavie CJ, De Schutter A, Patel DA, et al. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the 'obesity paradox'. J Am Coll Cardiol. 2012; 60: 1374-1380.
91. De Schutter A, Lavie CJ, Kachur S, et al. Body composition and mortality in a large cohort with preserved ejection fraction: untangling the obesity paradox. Mayo Clin Proc 2014; 89: 1072-1079.
92. Coutinho T, Goel K, Correa de, Sa D, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011; 57: 1877-1886.
93. McAuley PA, Kokkinos PF, Oliveira RB, et al. Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years. Mayo Clin Proc 2010; 85: 115-121.
94. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
95. Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol 2014; 173: 20-28.
96. Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 2012; 98: 1763-1777.
97. Paquot N, Castillo MJ, Lefebvre PJ, et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-1319.
98. Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011; 96: E146-E150.
99. Huvers FC, Popa C, Netea MG, et al. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007; 66: 558-559.
100. Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-1668.
101. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-1677.
102. Goldfine AB, Fonseca V, Jablonski KA, et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2013; 159: 1-12.
103. Farh KK, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015; 518: 337-343.
104. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 374: 1093-1094.
105. Vickers SP, Cheetham SC, Headland KR, et al. Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes 2014; 7: 265-275.
106. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015; 21: 512-517.
107. Welbourn R, le Roux CW, Owen-Smith A, et al. Why the NHS should do more bariatric surgery; how much should we do? BMJ 2016; 353: i1472.